Journal of VitreoRetinal Diseases最新文献_第9页

"Macular Sinkhole" With Secondary Choroidal Neovascularization. 伴有继发性脉络膜新生血管的 "黄斑天坑"。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-31 DOI: 10.1177/24741264241269467

Dillan Patel, Robert M Carroll

引用次数: 0

Retinal Toxicity Secondary to Suprachoroidal Migration of Mitomycin-C. 丝裂霉素-C在脉络膜上迁移引起的视网膜毒性

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-31 DOI: 10.1177/24741264241269533

Karim Dirani, Cesar Alfaro, Faisal Ridha Al-Timimi, Daniel Juzych, Pradeepa Yoganathan

引用次数: 0

Update on Retinal Drug Safety: Proceedings of the ASRS ReST Committee Webinar Part 1. 视网膜药物安全的最新进展：ASRS ReST 委员会网络研讨会第一部分会议记录。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-22 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241261441

Jessica M Girgis, Caroline R Baumal, Andre J Witkin, Lejla Vajzovic, Roger A Goldberg, Peter Kaiser, J Fernando Arevalo, Netan Choudhry, Eric Schneider, Homayoun Tabandeh, Robert Wong

{"title":"Update on Retinal Drug Safety: Proceedings of the ASRS ReST Committee Webinar Part 1.","authors":"Jessica M Girgis, Caroline R Baumal, Andre J Witkin, Lejla Vajzovic, Roger A Goldberg, Peter Kaiser, J Fernando Arevalo, Netan Choudhry, Eric Schneider, Homayoun Tabandeh, Robert Wong","doi":"10.1177/24741264241261441","DOIUrl":"https://doi.org/10.1177/24741264241261441","url":null,"abstract":"Purpose: To review the first Research and Safety in Therapeutics (ReST) Committee webinar and summarize the most current recommendations regarding diagnosis and management. Methods: The ReST Committee is comprised of members of the American Society of Retina Surgeons (ASRS). At regular internal meetings, safety issue reports from the website are reviewed. A webinar series was started in 2021 to update members on multiple relevant potential safety events. Results: Topics reviewed in the webinar included pentosan polysulfate sodium (Elmiron) maculopathy, intraocular pressure elevation reported with the aflibercept prefilled syringe (PFS), and brolucizumab-associated inflammation with occlusive retinal vasculitis. Retinal toxicity related to intraoperative medications was reviewed, including hemorrhagic occlusive retinal vasculitis after intraocular vancomycin, dilution errors with intravitreal aminoglycosides, inadvertent overdoses of cefuroxime after cataract surgery, and toxic posterior segment syndrome after dropless cataract surgery using compounded triamcinolone-moxifloxacin. Indocyanine green toxicity has been reported after its use as an adjuvant during macular hole surgery. Conclusions: The past decade has seen advances in retinal pharmaceuticals and drug-delivery devices. The ASRS ReST Committee collects data from its website reporting system to inform members about up-to-date pharmaceutical and device safety concerns. Recently, a webinar was used to inform members of pigmentary maculopathy associated with pentosan polysulfate sodium, safety regarding the aflibercept PFS, intraocular inflammation and occlusive retinal vasculitis secondary to brolucizumab, and retinal toxicity from intraoperative ocular medications.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 5","pages":"500-507"},"PeriodicalIF":0.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142336452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases. 用于治疗视网膜和脉络膜疾病的扩展眼内给药平台。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-22 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241267065

Charles C Wykoff, Baruch D Kuppermann, Carl D Regillo, Margaret Chang, Seenu M Hariprasad, Jay S Duker, Syed Altaf, Saïd Saïm

{"title":"Extended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases.","authors":"Charles C Wykoff, Baruch D Kuppermann, Carl D Regillo, Margaret Chang, Seenu M Hariprasad, Jay S Duker, Syed Altaf, Saïd Saïm","doi":"10.1177/24741264241267065","DOIUrl":"https://doi.org/10.1177/24741264241267065","url":null,"abstract":"Purpose: To review sustained-release intraocular platforms used to treat diseases of the retina and choroid. Methods: A literature review of the current applications of biomaterials for sustained-release therapy in retinal and choroidal diseases was performed. Results: Retinal and choroidal diseases, such as neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), diabetic macular edema (DME), and uveitis, are commonly treated using intravitreal (IVT) therapies that require frequent IVT injections. Multiple sustained-release options for IVT therapy have been approved by the US Food and Drug Administration for the treatment of inflammatory eye diseases, including noninfectious uveitis, infectious diseases, and exudative retinal diseases (eg, retinal venous occlusive disease and DME) using drugs such as fluocinolone acetonide, ganciclovir, and dexamethasone. The platforms for these drugs are biodegradable or nonbiodegradable. They use biomaterials such as polymers and hydrogels and are typically implanted surgically or injected into the vitreous, where they release the drug gradually over months or years. Building on these technologies, novel platforms are being studied that are intended to treat conditions including nAMD, DR, DME, and uveitis. These platforms are being tested for their safety, efficacy, and ability to reduce the injection and visit burden. Conclusions: Multiple sustained-release ocular drug-delivery platforms are currently commercially available, and many new sustained-release IVT platforms are being investigated. The hope is that meaningfully reducing the injection burden by extending intervals between treatments while maintaining optimal efficacy will improve long-term outcomes.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 5","pages":"577-586"},"PeriodicalIF":0.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential New Phenotypic Presentation of Pentosan Polysulfate Sodium Maculopathy. 多硫酸戊聚糖钠黄斑病的潜在新表型表现。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-22 DOI: 10.1177/24741264241271697

Sean Ghiam, Ash Pirouz, Sean D Adrean

{"title":"Potential New Phenotypic Presentation of Pentosan Polysulfate Sodium Maculopathy.","authors":"Sean Ghiam, Ash Pirouz, Sean D Adrean","doi":"10.1177/24741264241271697","DOIUrl":"10.1177/24741264241271697","url":null,"abstract":"Purpose: To describe a potential new phenotypic presentation of pentosan polysulfate sodium maculopathy. Methods: An observational case was analyzed. Results: A 55-year-old woman with interstitial cystitis who was treated with oral pentosan polysulfate sodium for 10 years presented with reports of decreased vision and metamorphopsia that had worsened over the past 3 months. On funduscopic examination, there were bilateral areas of retinal pigment epithelial hyperplasia inferior to the fovea with a surrounding halo of drusenoid material. Neurosensory retinal detachments with drusenoid deposition at the edges of the detachment were seen on spectral-domain optical coherence tomography. Conclusions: These findings could be mistaken for age-related macular degeneration, central serous retinopathy, Best disease, or adult vitelliform dystrophy. In this case, a review of pertinent medications assisted in making the diagnosis of toxic maculopathy. Proper diagnosis and prompt discontinuation of the inciting medication are necessary to avoid the risk for potentially irreversible retinal damage and vision loss.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241271697"},"PeriodicalIF":0.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of Rhegmatogenous Retinal Detachment Repair in Pseudophakic Eyes With Multifocal vs Monofocal Intraocular Lenses. 配戴多焦与单焦人工晶体的假性视网膜脱离修复术的疗效。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-22 DOI: 10.1177/24741264241271656

Abtin Shahlaee, Rachel N Israilevich, Raziyeh Mahmoudzadeh, Mirataollah Salabati, Taku Wakabayashi, Yoshihiro Yonekawa, Michael A Klufas

{"title":"Outcomes of Rhegmatogenous Retinal Detachment Repair in Pseudophakic Eyes With Multifocal vs Monofocal Intraocular Lenses.","authors":"Abtin Shahlaee, Rachel N Israilevich, Raziyeh Mahmoudzadeh, Mirataollah Salabati, Taku Wakabayashi, Yoshihiro Yonekawa, Michael A Klufas","doi":"10.1177/24741264241271656","DOIUrl":"10.1177/24741264241271656","url":null,"abstract":"Purpose: To compare the anatomic and visual acuity (VA) outcomes of rhegmatogenous retinal detachment (RRD) repair in eyes with a multifocal intraocular lens (IOLs) and eyes with monofocal IOLs. Methods: This retrospective matched-cohort study comprised pseudophakic eyes that had pars plana vitrectomy (PPV) or PPV with scleral buckling for RRD. Eyes with multifocal IOLs (multifocal group) were matched with eyes with monofocal IOLs (control group) in a 1:2 ratio for age, sex, primary surgeon, timing of surgery from presentation, type of surgery, and macular status. Results: The multifocal group included 67 eyes and the control group, 134 eyes. The mean (±SD) follow-up was 785 ± 595 days and 746 ± 566 days, respectively (P = .57). Overall, the single-surgery anatomic success rate was 76.1% in the multifocal group and 86.6% in the control group (P = .06); 75.0% and 85.9%, respectively, for PPV (P = .06); and 100% for PPV with scleral buckling in both groups (P = 1.00). The mean final logMAR VA was 0.26 ± 0.34 (20/36 Snellen) in the multifocal group and 0.27 ± 0.36 (20/37 Snellen) in the control group (P = .60). Conclusions: In pseudophakic eyes with an RRD, there was a trend toward better single-surgery anatomic success in eyes with a monofocal IOL than in eyes with a multifocal IOL treated with PPV, with similar anatomic outcomes for PPV with scleral buckling. Visual outcomes were similar between the groups and significantly improved compared with baseline.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241271656"},"PeriodicalIF":0.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Faricimab Treatment of Polypoidal Choroidal Vasculopathy Resistant to Intravitreal Ranibizumab Injections and Ranibizumab Port Delivery (Susvimo). 法利珠单抗治疗对玻璃体内注射雷珠单抗和雷珠单抗门给药(Susvimo)耐药的多形性脉络膜血管病。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-22 DOI: 10.1177/24741264241271739

Jeffrey Bloom, Rami Madani, Ali J Haidar, Tarek Alasil

{"title":"Faricimab Treatment of Polypoidal Choroidal Vasculopathy Resistant to Intravitreal Ranibizumab Injections and Ranibizumab Port Delivery (Susvimo).","authors":"Jeffrey Bloom, Rami Madani, Ali J Haidar, Tarek Alasil","doi":"10.1177/24741264241271739","DOIUrl":"10.1177/24741264241271739","url":null,"abstract":"Purpose: To report a case of polypoidal choroidal vasculopathy (PCV) recalcitrant to treatment with ranibizumab and with a ranibizumab port delivery system (Susvimo) but responsive to faricimab-svoa. Methods: A case and its findings were analyzed. Results: A 69-year-old Filipino man with PCV in the left eye was treated for 2 years with multiple ranibizumab intravitreal (IVT) injections followed by ranibizumab port delivery combined with rescue ranibizumab IVT injections, with no significant response clinically or on imaging. The visual acuity (VA) worsened to 20/100 OD. IVT treatment was switched to faricimab-svoa injections. After 2 injections, there was significant improvement on optical coherence tomography and in VA (20/60). Conclusions: This case shows the potential therapeutic benefits of targeting angiopoietin-2 in addition to vascular endothelial growth factor to treat PCV refractory to ranibizumab. Faricimab may provide an alternative to therapy with ranibizumab and verteporfin photodynamic therapy for the treatment of PCV.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241271739"},"PeriodicalIF":0.5,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ophthalmic Outcomes After Silicone Oil Removal. 硅油去除后的眼科疗效

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-15 DOI: 10.1177/24741264241271645

George Jiao, Paras P Shah, Eric P Shakin, Jessica G Lee, Philip J Ferrone, David Y Rhee, Juan M Romero, Brett J Rosenblatt, Kenneth B Graham, James Lin

{"title":"Ophthalmic Outcomes After Silicone Oil Removal.","authors":"George Jiao, Paras P Shah, Eric P Shakin, Jessica G Lee, Philip J Ferrone, David Y Rhee, Juan M Romero, Brett J Rosenblatt, Kenneth B Graham, James Lin","doi":"10.1177/24741264241271645","DOIUrl":"10.1177/24741264241271645","url":null,"abstract":"Purpose: To describe the ophthalmic outcomes and complications after silicone oil (SO) removal. Methods: This nonrandomized retrospective review comprised patients who had SO removal from January 2020 to December 2022. Data collected included patient demographics, visual acuity (VA), intraocular pressure (IOP), initial tamponade, indication for SO placement, duration of SO in the eye, indication for SO removal, cataract progression, rates of retinal redetachment, cornea-related complications, additional surgical interventions, and other complications. Results: The study comprised 107 eyes (mean age, 56.6 years; 67% male). The most common indications for SO tamponade were rhegmatogenous retinal detachment (RRD), RRD with proliferative vitreoretinopathy (PVR), and tractional RD. The mean SO tamponade duration was 9.3 months and was longer for patients who did not have redetachment than for those who had detachment (10 months vs 6.8 months; P = .024). The mean preoperative logMAR VA had significantly improved by the final follow-up (1.44 vs 1.19; P < .001). The mean IOP was 16.43 mm Hg preoperatively and 16.81 mm Hg at the final visit (P = .672). Retinal redetachment occurred in 20.6% of patients, and the anatomic success rate at the final follow-up was 86.0%. A history of recurrent detachment and PVR was not associated with increased rates of postoperative redetachment. The overall rate of hypotony was 3.7% and of ocular hypertension, 7.5%. Significant cataract progression occurred in 69% of eyes. Conclusions: After SO removal, there was an overall improvement in VA and a stable IOP. Cataract progression was the most common complication. Although there is a risk for redetachment after SO removal, it may not have a detrimental effect on redetachment rates with a longer duration of SO tamponade.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241271645"},"PeriodicalIF":0.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Choriocapillaris Loss in a Pediatric Patient With Congenital Cytomegalovirus Seen on Optical Coherence Tomography Angiography. 光学相干断层扫描血管造影中发现的先天性巨细胞病毒小儿患者的绒毛膜缺失。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-12 DOI: 10.1177/24741264241271707

Lindsay K Kozek, David Morcos, Sandra Hoyek, Nimesh A Patel

{"title":"Choriocapillaris Loss in a Pediatric Patient With Congenital Cytomegalovirus Seen on Optical Coherence Tomography Angiography.","authors":"Lindsay K Kozek, David Morcos, Sandra Hoyek, Nimesh A Patel","doi":"10.1177/24741264241271707","DOIUrl":"10.1177/24741264241271707","url":null,"abstract":"Purpose: To describe choriocapillaris loss on optical coherence tomography angiography (OCTA) imaging in a pediatric patient with congenital cytomegalovirus (CMV). Methods: A case was evaluated. Results: A 7-year-old female patient was referred for retinal evaluation of maculopathy in the right eye. She was diagnosed with congenital CMV at 14 months of age, at which time treatment was not deemed necessary. At 7 years of age, the patient was asymptomatic with 20/20 Snellen visual acuity. Funduscopy and colored fundus photographs showed macular scarring. Ancillary testing was performed, with retinal pigment epithelium alterations and disruption of the outer retinal layers seen on OCT and choriocapillaris loss in the area of the macular scar seen on OCTA. Conclusions: For patients with congenital CMV, OCTA imaging can show significant changes in choriocapillaris function. These changes do not necessarily correlate with visual function parameters. OCTA may be useful as an additional screening or surveillance modality for patients with congenital CMV or CMV retinitis.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241271707"},"PeriodicalIF":0.5,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2024 Distinguished Contributor Awards. 2024 杰出贡献奖。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-08-08 eCollection Date: 2024-07-01 DOI: 10.1177/24741264241263405

引用次数: 0